OMER
Omeros Corporation
Price Chart
Latest Quote
$17.12
+0.83 (+5.08%)
Current Price
| Previous Close | $16.29 |
| Open | $16.30 |
| Day High | $17.15 |
| Day Low | $16.20 |
| Volume | 304,348 |
Stock Information
| Shares Outstanding | 72.39M |
| Total Debt | $296.87M |
| Cash Equivalents | $131.95M |
| Revenue | $38.42M |
| Net Income | $116.53M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.24B |
| P/E Ratio | 14.03 |
| EPS (TTM) | $1.22 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.34B |
| Sales | $38.42M |
| Income | $116.53M |
| Book/sh | $-0.71 |
| Cash/sh | $1.82 |
| Employees | 175 |
Financial Ratios
| Quick Ratio | 1.61 |
| Current Ratio | 1.95 |
Returns & Margins
| ROA | -18.68% |
| Gross Margin | 38.34% |
| Operating Margin | 0.26% |
| Profit Margin | 324.88% |
Ownership
| Insider Ownership | 4.08% |
| Institutional Ownership | 51.34% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 13.92 |
| PEG | 0.81 |
| P/S | 32.25 |
| P/B | -24.04 |
Analyst Data
| Recommendation | buy |
| Target Price | $27.50 |
Technical Indicators
| SMA20 | $17.96 |
| SMA50 | $18.49 |
| SMA200 | $13.40 |
| RSI | 39.88 |
| ATR | 0.8800 |
| Shares Float | 69.29M |
| Short Float | 16.30% |
| Short Ratio | 7.54 |
| Volatility | 2.57 |
| Rel Volume | 0.29 |
Performance History
| Week | +3.43% |
| Month | -11.90% |
| Quarter | +46.67% |
| 6 Months | +16.68% |
| YTD | +4.50% |
| Year | +126.71% |
| 3 Years | +1291.62% |
| 5 Years | +175.19% |
| 10 Years | +114.23% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $17.12 | 304,348 |
| 2026-10-26 | $16.29 | 741,100 |
| 2026-10-23 | $16.57 | 699,400 |
| 2026-10-22 | $16.86 | 737,100 |
| 2026-10-21 | $16.26 | 698,200 |
| 2026-10-20 | $16.55 | 725,300 |
| 2026-10-19 | $16.35 | 1,382,100 |
| 2026-10-16 | $16.20 | 3,963,900 |
| 2026-10-15 | $18.79 | 931,400 |
| 2026-10-14 | $18.43 | 904,900 |
| 2026-10-13 | $18.88 | 994,000 |
| 2026-10-12 | $19.63 | 1,065,200 |
| 2026-10-09 | $19.83 | 793,900 |
| 2026-10-08 | $19.12 | 899,900 |
| 2026-10-07 | $18.75 | 622,900 |
| 2026-10-06 | $18.51 | 1,035,000 |
| 2026-10-05 | $18.90 | 1,068,100 |
| 2026-10-02 | $18.61 | 956,400 |
| 2026-10-01 | $18.47 | 1,236,800 |
| 2026-09-30 | $19.04 | 1,365,400 |
| 2026-09-29 | $19.25 | 841,700 |
| 2026-09-28 | $19.43 | 1,026,400 |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
đ° Latest News
No news articles available at the moment. Check back later for updates on OMER.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | - | - |
| Cost Of Revenue | - | - | - | - |
| Expenses | ||||
| Total Expenses | $122,796,000 | $166,953,000 | $164,530,000 | $163,389,000 |
| Other Income Expense | $114,944,000 | $19,000 | $4,112,000 | - |
| Net Non Operating Interest Income Expense | $5,056,000 | $-13,390,000 | $-14,502,000 | $-18,640,000 |
| Operating Expense | $122,796,000 | $166,953,000 | $164,530,000 | $163,389,000 |
| General And Administrative Expense | $41,500,000 | $47,430,000 | $49,660,000 | $50,668,000 |
| Interest Expense | - | $24,675,000 | $30,844,000 | $22,702,000 |
| Interest Expense Non Operating | - | $24,675,000 | $30,844,000 | $22,702,000 |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,808,000 | $-182,629,000 | $-174,920,000 | $-182,029,000 |
| Net Interest Income | $5,056,000 | $-13,390,000 | $-14,502,000 | $-18,640,000 |
| Interest Income | $5,056,000 | $11,285,000 | $16,342,000 | $4,062,000 |
| Normalized Income | $-95,613,760 | $-182,644,010 | $-179,032,000 | $-182,029,000 |
| Net Income From Continuing And Discontinued Operation | $-3,350,000 | $-156,815,000 | $-117,813,000 | $47,417,000 |
| Total Operating Income As Reported | $-122,796,000 | $-166,953,000 | $-164,530,000 | $-163,389,000 |
| Net Income Common Stockholders | $-3,350,000 | $-156,815,000 | $-117,813,000 | $47,417,000 |
| Net Income | $-3,350,000 | $-156,815,000 | $-117,813,000 | $47,417,000 |
| Net Income Including Noncontrolling Interests | $-3,350,000 | $-156,815,000 | $-117,813,000 | $47,417,000 |
| Net Income Discontinuous Operations | $1,458,000 | $25,814,000 | $57,107,000 | $229,446,000 |
| Net Income Continuous Operations | $-4,808,000 | $-182,629,000 | $-174,920,000 | $-182,029,000 |
| Pretax Income | $-2,796,000 | $-180,324,000 | $-174,920,000 | $-182,029,000 |
| Special Income Charges | $251,661,000 | $0 | $4,112,000 | $0 |
| Interest Income Non Operating | $5,056,000 | $11,285,000 | $16,342,000 | $4,062,000 |
| Operating Income | $-122,796,000 | $-166,953,000 | $-164,530,000 | $-163,389,000 |
| Gross Profit | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.05 | $-2.70 | $-1.88 | $0.76 |
| Basic EPS | $-0.05 | $-2.70 | $-1.88 | $0.76 |
| Other | ||||
| Tax Effect Of Unusual Items | $24,138,240 | $3,990 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-236,776,000 | $-154,718,000 | $-147,268,000 | $-158,375,000 |
| Total Unusual Items | $114,944,000 | $19,000 | $4,112,000 | $0 |
| Total Unusual Items Excluding Goodwill | $114,944,000 | $19,000 | $4,112,000 | $0 |
| Reconciled Depreciation | $964,000 | $950,000 | $920,000 | $952,000 |
| EBITDA (Bullshit earnings) | $-121,832,000 | $-154,699,000 | $-143,156,000 | $-158,375,000 |
| EBIT | $-122,796,000 | $-155,649,000 | $-144,076,000 | $-159,327,000 |
| Diluted Average Shares | $63,510,201 | $58,170,931 | $62,739,227 | $62,737,091 |
| Basic Average Shares | $63,510,201 | $58,170,931 | $62,739,227 | $62,737,091 |
| Diluted NI Availto Com Stockholders | $-3,350,000 | $-156,815,000 | $-117,813,000 | $47,417,000 |
| Tax Provision | $2,012,000 | $2,305,000 | $0 | $0 |
| Gain On Sale Of Business | $237,594,000 | - | - | - |
| Other Special Charges | $-14,067,000 | - | $-4,112,000 | - |
| Gain On Sale Of Security | $-136,717,000 | $19,000 | - | - |
| Research And Development | $81,296,000 | $119,523,000 | $114,870,000 | $112,721,000 |
| Selling General And Administration | $41,500,000 | $47,430,000 | $49,660,000 | $50,668,000 |
| Other Gand A | $36,838,000 | $41,070,000 | $42,520,000 | $42,626,000 |
| Salaries And Wages | $4,662,000 | $6,360,000 | $7,140,000 | $8,042,000 |
Fetched: 2026-10-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-121,231,000 | $-182,609,000 | $-24,983,000 | $85,684,000 |
| Total Assets | $325,632,000 | $277,079,000 | $378,269,000 | $590,969,000 |
| Total Non Current Assets | $109,965,000 | $142,959,000 | $160,371,000 | $147,733,000 |
| Other Non Current Assets | $1,054,000 | $1,054,000 | $1,054,000 | $1,054,000 |
| Non Current Accounts Receivable | $96,435,000 | $124,266,000 | $138,736,000 | $123,425,000 |
| Current Assets | $215,667,000 | $134,120,000 | $217,898,000 | $443,236,000 |
| Other Current Assets | $7,595,000 | $7,166,000 | $8,581,000 | $6,300,000 |
| Receivables | $36,268,000 | $36,822,000 | $37,469,000 | $242,018,000 |
| Other Receivables | $29,825,000 | $29,882,000 | $30,745,000 | $29,052,000 |
| Accounts Receivable | $6,443,000 | $6,940,000 | $6,724,000 | $212,966,000 |
| Cash Cash Equivalents And Short Term Investments | $171,804,000 | $90,132,000 | $171,848,000 | $194,918,000 |
| Cash And Cash Equivalents | $9,660,000 | $3,400,000 | $7,105,000 | $11,009,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $215,938,000 | $184,183,000 | $206,050,000 | $304,278,000 |
| Total Debt | $239,143,000 | $207,020,000 | $236,458,000 | $342,023,000 |
| Long Term Debt And Capital Lease Obligation | $215,780,000 | $180,049,000 | $231,298,000 | $243,332,000 |
| Long Term Debt | $208,535,000 | $166,583,000 | $213,155,000 | $220,906,000 |
| Current Debt And Capital Lease Obligation | $23,363,000 | $26,971,000 | $5,160,000 | $98,691,000 |
| Current Debt | $17,063,000 | $21,000,000 | - | $94,381,000 |
| Other Current Borrowings | $17,063,000 | $21,000,000 | - | $94,381,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $446,863,000 | $459,688,000 | $403,252,000 | $505,285,000 |
| Total Non Current Liabilities Net Minority Interest | $368,801,000 | $380,162,000 | $349,936,000 | $368,902,000 |
| Other Non Current Liabilities | $147,319,000 | $195,612,000 | $116,550,000 | $125,126,000 |
| Current Liabilities | $78,062,000 | $79,526,000 | $53,316,000 | $136,383,000 |
| Other Current Liabilities | $20,547,000 | $20,645,000 | $8,576,000 | $1,152,000 |
| Current Deferred Liabilities | $2,473,000 | $183,000 | - | - |
| Payables And Accrued Expenses | $21,331,000 | $22,859,000 | $32,200,000 | $29,875,000 |
| Interest Payable | $616,000 | $2,667,000 | $4,242,000 | $5,172,000 |
| Payables | $5,910,000 | $5,960,000 | $7,712,000 | $5,989,000 |
| Total Tax Payable | $1,146,000 | $55,000 | - | $4,871,000 |
| Income Tax Payable | $1,146,000 | $55,000 | - | $4,871,000 |
| Accounts Payable | $4,764,000 | $5,905,000 | $7,712,000 | $5,989,000 |
| Equity | ||||
| Common Stock Equity | $-121,231,000 | $-182,609,000 | $-24,983,000 | $85,684,000 |
| Total Equity Gross Minority Interest | $-121,231,000 | $-182,609,000 | $-24,983,000 | $85,684,000 |
| Stockholders Equity | $-121,231,000 | $-182,609,000 | $-24,983,000 | $85,684,000 |
| Retained Earnings | $-913,695,000 | $-910,345,000 | $-753,530,000 | $-635,717,000 |
| Other | ||||
| Ordinary Shares Number | $71,670,791 | $58,044,465 | $61,128,597 | $62,828,765 |
| Share Issued | $71,670,791 | $58,044,465 | $61,128,597 | $62,828,765 |
| Tangible Book Value | $-121,231,000 | $-182,609,000 | $-24,983,000 | $85,684,000 |
| Invested Capital | $104,367,000 | $4,974,000 | $188,172,000 | $400,971,000 |
| Working Capital | $137,605,000 | $54,594,000 | $164,582,000 | $306,853,000 |
| Capital Lease Obligations | $13,545,000 | $19,437,000 | $23,303,000 | $26,736,000 |
| Total Capitalization | $87,304,000 | $-16,026,000 | $188,172,000 | $306,590,000 |
| Additional Paid In Capital | $791,748,000 | $727,156,000 | $727,936,000 | $720,773,000 |
| Capital Stock | $716,000 | $580,000 | $611,000 | $628,000 |
| Common Stock | $716,000 | $580,000 | $611,000 | $628,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Accrued Expenses | $5,702,000 | $4,501,000 | $2,088,000 | $444,000 |
| Long Term Capital Lease Obligation | $7,245,000 | $13,466,000 | $18,143,000 | $22,426,000 |
| Current Deferred Revenue | $2,473,000 | $183,000 | - | - |
| Current Capital Lease Obligation | $6,300,000 | $5,971,000 | $5,160,000 | $4,310,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,348,000 | $8,868,000 | $7,380,000 | $6,665,000 |
| Current Accrued Expenses | $15,421,000 | $16,899,000 | $24,488,000 | $23,886,000 |
| Net PPE | $12,476,000 | $17,639,000 | $20,581,000 | $23,254,000 |
| Accumulated Depreciation | $-12,036,000 | $-11,072,000 | $-10,241,000 | $-9,548,000 |
| Gross PPE | $24,512,000 | $28,711,000 | $30,822,000 | $32,802,000 |
| Other Properties | $22,775,000 | $26,974,000 | $29,085,000 | $31,101,000 |
| Machinery Furniture Equipment | $1,737,000 | $1,737,000 | $1,737,000 | $1,701,000 |
| Other Short Term Investments | $162,144,000 | $86,732,000 | $164,743,000 | $183,909,000 |
| Buildings And Improvements | - | $14,961,000 | $18,631,000 | $21,762,000 |
| Properties | - | $0 | $0 | $0 |
Fetched: 2026-10-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-116,159,000 | $-148,968,000 | $74,300,000 | $-86,596,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-116,094,000 | $-148,803,000 | $74,726,000 | $-86,483,000 |
| Cash Flow From Continuing Operating Activities | $-116,094,000 | $-148,803,000 | $74,726,000 | $-86,483,000 |
| Operating Gains Losses | $-255,205,000 | - | $-4,112,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-65,000 | $-165,000 | $-426,000 | $-113,000 |
| Investing Cash Flow | $164,523,000 | $82,217,000 | $27,454,000 | $-127,564,000 |
| Cash Flow From Continuing Investing Activities | $164,523,000 | $82,217,000 | $27,454,000 | $-127,564,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-11,851,000 | $-4,654,000 | $0 |
| Issuance Of Capital Stock | $39,343,000 | $0 | $0 | $0 |
| Financing Cash Flow | $-42,169,000 | $62,881,000 | $-106,084,000 | $124,248,000 |
| Cash Flow From Continuing Financing Activities | $-42,169,000 | $62,881,000 | $-106,084,000 | $124,248,000 |
| Net Common Stock Issuance | $39,343,000 | $-11,851,000 | $-4,654,000 | $0 |
| Common Stock Issuance | $39,343,000 | $0 | $0 | $0 |
| Net Other Financing Charges | - | $115,525,000 | - | $125,000,000 |
| Other | ||||
| Repayment Of Debt | $-89,163,000 | $-41,340,000 | $-101,580,000 | $-1,167,000 |
| Interest Paid Supplemental Data | $35,419,000 | $35,686,000 | $29,923,000 | $19,178,000 |
| Income Tax Paid Supplemental Data | $153,000 | $165,000 | $3,292,000 | $80,000 |
| End Cash Position | $9,660,000 | $3,400,000 | $7,105,000 | $11,009,000 |
| Beginning Cash Position | $3,400,000 | $7,105,000 | $11,009,000 | $100,808,000 |
| Changes In Cash | $6,260,000 | $-3,705,000 | $-3,904,000 | $-89,799,000 |
| Proceeds From Stock Option Exercised | $7,651,000 | $547,000 | $150,000 | $415,000 |
| Common Stock Payments | $0 | $-11,851,000 | $-4,654,000 | $0 |
| Net Issuance Payments Of Debt | $-89,163,000 | $-41,340,000 | $-101,580,000 | $-1,167,000 |
| Net Long Term Debt Issuance | $-89,163,000 | $-41,340,000 | $-101,580,000 | $-1,167,000 |
| Long Term Debt Payments | $-89,163,000 | $-41,340,000 | $-101,580,000 | $-1,167,000 |
| Net Investment Purchase And Sale | $-75,412,000 | $82,382,000 | $27,880,000 | $-127,451,000 |
| Sale Of Investment | $109,900,000 | $1,069,767,000 | $1,046,482,000 | $301,594,000 |
| Purchase Of Investment | $-185,312,000 | $-987,385,000 | $-1,018,602,000 | $-429,045,000 |
| Net PPE Purchase And Sale | $239,935,000 | $-165,000 | $-426,000 | $-113,000 |
| Sale Of PPE | $240,000,000 | $0 | $0 | - |
| Purchase Of PPE | $-65,000 | $-165,000 | $-426,000 | $-113,000 |
| Change In Working Capital | $33,716,000 | $35,286,000 | $247,424,000 | $-119,358,000 |
| Change In Payables And Accrued Expense | $4,582,000 | $-5,239,000 | $4,682,000 | $-10,665,000 |
| Change In Prepaid Assets | $-1,311,000 | $517,000 | $-2,978,000 | $934,000 |
| Change In Receivables | $30,445,000 | $40,008,000 | $245,720,000 | $-109,627,000 |
| Changes In Account Receivables | $-3,178,000 | $357,000 | $205,125,000 | $-175,066,000 |
| Other Non Cash Items | $-37,128,000 | $-34,327,000 | $-54,629,000 | $-29,566,000 |
| Stock Based Compensation | $8,192,000 | $10,493,000 | $11,650,000 | $14,072,000 |
| Unrealized Gain Loss On Investment Securities | $136,717,000 | $-19,000 | $0 | - |
| Amortization Of Securities | $0 | $-4,371,000 | $-8,714,000 | $0 |
| Depreciation Amortization Depletion | $964,000 | $950,000 | $920,000 | $952,000 |
| Depreciation And Amortization | $964,000 | $950,000 | $920,000 | $952,000 |
| Gain Loss On Sale Of Business | $-237,594,000 | $0 | $0 | $0 |
| Net Income From Continuing Operations | $-3,350,000 | $-156,815,000 | $-117,813,000 | $47,417,000 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Sale Of Business | - | - | $0 | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | - |
| Change In Payable | - | - | - | - |
| Change In Account Payable | - | - | - | - |
Fetched: 2026-10-19